The MammaPrint is a genomic test that analyzes the activity of certain genes in early-stage breast cancer. The MammaPrint Test is used in two ways:
Who’s eligible for the MammaPrint test?
MammaPrint can only be used to analyze early-stage breast cancers that are:
In both the United States and internationally, MammaPrint can be used to analyze cancers that are hormone-receptor-positive and hormone-receptor-negative.
How does the MammaPrint test work?
The MammaPrint test looks at the activity of 70 genes and then calculates a recurrence score that is either low risk or high risk.
If a patient decide to have the MammaPrint test, a patient and a patient’s doctor will consider a number of factors when deciding on whether to add chemotherapy to a patient treatment plan, including: